Shares in Reata Pharmaceuticals Inc. have rocketed on positive data for omaveloxolone, one of the Nrf2 activators it reacquired the rights to less than a week ago from AbbVie Inc..
Reata Friedreich's Ataxia Drug Shows Late-Stage MOXIe
Reacquiring rights to omaveloxolone from AbbVie looks great business
Analysts have been surprised by positive pivotal data for omaveloxolone, one of Reata's Nrf2 activators – along with bardoxolone – which the company is buying back from AbbVie for $330m.
More from Rare Diseases
More from Scrip
Recent moves in the industry include C-suite changes at 23andMe, Biomea Fusion & Alector, plus Bicycle Therapeutics acquires chief medical officer from ImmunoGen.
• By
Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.
• By
Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.